NEWS
Free Institutional Consultancy Services
New Feature: Compare Your Institution with the Previous Year
Find a Professional: Explore Experts Across 197 Disciplines in 220 Countries!
Find a Professional
Print Your Certificate
New! Young University / Institution Rankings 2025
New! Art & Humanities Rankings 2025
New! Social Sciences and Humanities Rankings 2025
Highly Cited Researchers 2025
AD
Scientific Index 2025
Scientist Rankings
University Rankings
Subject Rankings
Country Rankings
login
Login
person_add
Register
insights
H-Index Rankings
insights
i10 Productivity Rankings
format_list_numbered
Citation Rankings
subject
University Subject Rankings
school
Young Universities
format_list_numbered
Top 100 Scientists
format_quote
Top 100 Institutions
format_quote
Compare & Choose
local_fire_department
Country Reports
person
Find a Professional
Rutugandha Paranjpe
University of Houston - Houston / United States
Economics & Econometrics / Economics
AD Scientific Index ID: 4891049
Registration, Add Profile,
Premium Membership
Print Your Certificate
Ranking &
Analysis
Job
Experiences (0)
Education
Information (0)
Published Books (0)
Book Chapters (0)
Articles (0)
Presentations (0)
Lessons (0)
Projects (0)
Congresses (0)
Editorship, Referee &
Scientific Board (0 )
Patents /
Designs (0)
Academic Grants
& Awards (0)
Artistic
Activities (0)
Certificate / Course
/ Trainings (0)
Association &
Society Memberships (0)
Contact, Office
& Social Media
person_outline
Rutugandha Paranjpe's MOST POPULAR ARTICLES
1-)
Hydroxychavicol, a betel leaf component, inhibits prostate cancer through ROS-driven DNA damage and apoptosisSR Gundala, C Yang, R Mukkavilli, R Paranjpe, M Brahmbhatt, V Pannu, ...Toxicology and applied pharmacology 280 (1), 86-96, 2014772014
2-)
Piper betel leaf extract: anticancer benefits and bio-guided fractionation to identify active principles for prostate cancer managementR Paranjpe, SR Gundala, N Lakshminarayana, A Sagwal, G Asif, ...Carcinogenesis 34 (7), 1558-1566, 2013682013
3-)
Identifying adherence barriers to oral endocrine therapy among breast cancer survivorsR Paranjpe, G John, M Trivedi, S AbughoshBreast Cancer Research and Treatment 174 (2), 297-305, 2019412019
4-)
Neratinib in HER2-positive breast cancer patientsR Paranjpe, D Basatneh, G Tao, C De Angelis, S Noormohammed, ...Annals of Pharmacotherapy 53 (6), 612-620, 2019312019
5-)
Medication adherence to antihypertensive triple-combination therapy among patients enrolled in a medicare advantage planX Wang, H Chen, E Essien, J Wu, O Serna, R Paranjpe, S AbughoshJournal of managed care & specialty pharmacy 25 (6), 678-686, 2019292019
ARTICLES
Add your articles
We use cookies to personalize our website and offer you a better experience. If you accept cookies, we can offer you special services.
Cookie Policy
Accept